Business
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present clinical data from the
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present clinical data from the Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU), at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Jerusalem, Israel, August 29 – September 1, 2023. The Company and its collaborators will also present analyses on its prospective HCU natural history study, the prevalence of HCU, and the burden of HCU from the patient perspective highlighting the devastating nature of this rare metabolic disease over patients’ lifetimes and underscoring the urgent need for new treatments. In addition, the Company will present data on the clinical burden of HCU and the relationship between total homocysteine (tHcy) and clinical outcomes, which has been recognized as one of the highest ranked posters at SSIEM. Oral Presentation Pegtibatinase, an Investigational Enzyme Replacement Therapy for the Treatment of Classical Homocystinuria (HCU): Latest Findings from the COMPOSE Phase 1/2 TrialParallel Session: Clinical Studies and Outcomes IAugust 30, 9:45 – 10:00 a.m. IDT, Oren 2 Poster PresentationsPoster presentations will take place in the Exhibitions Hall (ICC) on August 29, 3:30 – 7:30 p.m. IDT; August 30, 7:30 a.m. – 8:35 p.m. IDT; August 31, 7:45 a.m. – 3:30 p.m. IDT; and September 1, 8:15 a.m. – 12:30 p.m. IDT. Clinical Characterization of Classical Homocystinuria Due to Cystathionine-beta Synthase Deficiency: Results from the ACAPPELLA StudyPoster B18Poster Section: Clinical Studies, Patient Reported Outcome Measures Clinical Burden of Classical Homocystinuria in the United States: A Retrospective Analysis of Optum Market ClarityPoster B36Poster Section: Clinical Studies, Patient Reported Outcome MeasuresAugust 30, 7:11 p.m. IDT, Exhibitions Hall (ICC) – Poster Walk & Highest Ranked Posters Validation of a Patient Identification Algorithm to Estimate the Prevalence of ClassicalHomocystinuria (HCU) in the United States (US)Poster B24Poster Section: Clinical Studies, Patient Reported Outcome Measures Understanding the Burden of Classical Homocystinuria (HCU) from the Patient’s Perspective: A Qualitative StudyPoster B102Poster Section: Inborn Erro...